Treatment of hypotension associated with hemodialysis

A method for identifying hemodialysis subjects for whom treatment with at least one physiologically compatible compound which, in combination with iron, binds nitric oxide is indicated, said method comprising:

• monitoring the subject's nitric oxide levels, and
• selecting those subjects having elevated nitric oxide levels for treatment with an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide sufficient to maintain the subject's nitric oxide levels within an acceptable range.

A method to determine what treatment is indicated for a subject at risk of developing hypotension associated with hemodialysis, said method comprising:

• monitoring the subject's nitric oxide levels, and
• identifying those subjects which display an elevated level of nitric oxide as suitable for treatment with an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide.

A method to determine what treatment is indicated for a subject at risk of developing hypotension associated with hemodialysis, said method comprising:

• monitoring the subject's endothelial nitric oxide synthase levels, and
• identifying those subjects which display an elevated level of endothelial nitric oxide synthase as suitable for treatment with an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide.

A composition comprising:

• a physiologically compatible compound which, in combination with iron, binds nitric oxide, and
• midodrine.

A method for the prevention and/or treatment of hypotension associated with hemodialysis, said method comprising administering to a subject in need thereof:

• an effective amount of at least one physiologically compatible compound which, in combination with iron, binds nitric oxide, and
• midodrine,
• wherein said compound and midodrine are administered separately or together.